Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines

被引：1
|
作者：
Sanchez de Prada, Laura [1 ]
Sanz Munoz, Ivan [2 ]
Castrodeza Sanz, Javier [1 ]
Ortiz de Lejarazu Leonardo, Raul [2 ]
Eiros Bouza, Jose Maria [2 ,3 ]
机构：
[1] Univ Valladolid, Hosp Clin, Valladolid 47003, Spain
[2] Ctr Nacl Gripe Valladolid, Valladolid 47009, Spain
[3] Hosp Univ Rio Hortega Valladolid, Valladolid 47012, Spain
来源：
VACCINES | 2020年 / 8卷 / 04期
关键词：
influenza A; Vaccines; adjuvanted Vaccines; SEASONAL INFLUENZA; INFECTION; VACCINATION; MORTALITY;
D O I：
10.3390/vaccines8040704
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: vaccination is the best approach to prevent influenza infections so far. Serological studies on the effect of different vaccine types are important to address vaccination campaigns and protect our population. In our study, we compared the serological response against influenza A subtypes using the non-adjuvanted influenza vaccine (NAIV) in adults and the elderly and the adjuvanted influenza vaccine (AIV) in the elderly. Methods: We performed a retrospective analysis by hemagglutination inhibition assay (HI) of serum samples right before and 28 days after seasonal influenza vaccination during the 1996-2017 seasons. Conclusions: The AIV presents better performance against the A(H3N2) subtype in the elderly whereas the NAIV induces a better response against A(H1N1)pdm09 in the same group.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 50 条
  • [31] AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial
    McElhaney, Janet E.
    Beran, Jiri
    Devaster, Jeanne-Marie
    Esen, Meral
    Launay, Odile
    Leroux-Roels, Geert
    Ruiz-Palacios, Guillermo M.
    van Essen, Gerrit A.
    Caplanusit, Adrian
    Claeyst, Carine
    Durandt, Christelle
    Duvalt, Xavier
    El Idrissit, Mohamed
    Falseyt, Ann R.
    Feldmant, Gregory
    Freyt, Sharon E.
    Gaitiert, Florence
    Hwang, Shinn-Jang
    Innist, Bruce L.
    Kovact, Martina
    Kremsnert, Peter
    McNeill, Shelly
    Nowakowskit, Andrzej
    Richardust, Jan Hendrik
    Trofat, Andrew
    Oostvogels, Lidia
    LANCET INFECTIOUS DISEASES, 2013, 13 (06): : 485 - 496
  • [32] Efficacy of swine influenza A virus vaccines against an H3N2 virus variant
    Lee, Jee Hoon
    Gramer, Marie Rene
    Joo, Han Soo
    CANADIAN JOURNAL OF VETERINARY RESEARCH-REVUE CANADIENNE DE RECHERCHE VETERINAIRE, 2007, 71 (03): : 207 - 212
  • [33] ANTIBODY-RESPONSES TO INACTIVATED INFLUENZA VACCINES AND PARTIAL PROTECTIVE EFFECT OF ANTI-NEURAMINIDASE ANTIBODY AGAINST EPIDEMICS OF A(H3N2) AND A(H1N1) INFLUENZA
    MAEDA, A
    OISHI, I
    MINEKAWA, Y
    KUNITA, N
    FUNAHASHI, S
    YAGURA, H
    BIKEN JOURNAL, 1979, 22 (03) : 91 - 98
  • [34] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
    Ma Teresa Herrera
    Yolanda Gonzalez
    Esmeralda Juárez
    Fernando Hernández-Sánchez
    Claudia Carranza
    Carmen Sarabia
    Silvia Guzman-Beltran
    Ma Eugenia Manjarrez
    Marcela Muñoz-Torrico
    Lourdes Garcia-Garcia
    Eduardo Sada
    Martha Torres
    BMC Infectious Diseases, 13
  • [35] Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial
    Folschweiller, Nicolas
    Vanden Abeele, Carline
    Chu, Laurence
    Van Damme, Pierre
    Garcia-Sastre, Adolfo
    Krammer, Florian
    Nachbagauer, Raffael
    Palese, Peter
    Solorzano, Alicia
    Bi, Dan
    David, Marie-Pierre
    Friel, Damien
    Innis, Bruce L.
    Koch, Juliane
    Mallett, Corey P.
    Rouxel, Ronan Nicolas
    Salaun, Bruno
    Vantomme, Valerie
    Verheust, Celine
    Struyf, Frank
    LANCET INFECTIOUS DISEASES, 2022, 22 (07): : 1062 - 1075
  • [36] Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season
    Imran, Mahrukh
    Puig-Barbera, Joan
    Ortiz, Justin R.
    Lopez-Gonzalez, Lorena
    Dean, Alex
    Bonafede, Machaon
    Haag, Mendel D. M.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (04)
  • [37] Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
    T. Menegon
    V. Baldo
    C. Bonello
    D. Dalla Costa
    A. Di Tommaso
    R. Trivello
    European Journal of Epidemiology, 1999, 15 : 573 - 576
  • [38] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
    Teresa Herrera, Ma
    Gonzalez, Yolanda
    Juarez, Esmeralda
    Hernandez-Sanchez, Fernando
    Carranza, Claudia
    Sarabia, Carmen
    Guzman-Beltran, Silvia
    Eugenia Manjarrez, Ma
    Munoz-Torrico, Marcela
    Garcia-Garcia, Lourdes
    Sada, Eduardo
    Torres, Martha
    BMC INFECTIOUS DISEASES, 2013, 13
  • [39] T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults
    Haralambieva, Iana H.
    Quach, Huy Quang
    Ovsyannikova, Inna G.
    Goergen, Krista M.
    Grill, Diane E.
    Poland, Gregory A.
    Kennedy, Richard B.
    VIRUSES-BASEL, 2022, 14 (12):
  • [40] Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
    Menegon, T
    Baldo, V
    Bonello, C
    Costa, DD
    Di Tommaso, A
    Trivello, R
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1999, 15 (06) : 573 - 576
12345